// Auto-generated - do not edit
export const substanceName = "Secobarbital";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Secobarbital.md","displayName":"DrugBank","size":16515},{"id":"isomerdesign","fileName":"ISOMERDESIGN - Secobarbital.md","displayName":"Isomer Design","size":724},{"id":"protestkit","fileName":"PROTESTKIT - Secobarbital.json","displayName":"Protest Kit","size":2965},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - Secobarbital.md","displayName":"PsychonautWiki","size":22016},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Secobarbital.md","displayName":"TripSit Factsheets","size":378},{"id":"wikipedia","fileName":"WIKIPEDIA - Secobarbital.md","displayName":"Wikipedia","size":6245}];
export const contents: Record<string, string> = {
  "drugbank": `# Secobarbital
*Source: https://go.drugbank.com/drugs/DB00418*

## Overview

### Description

This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.

### Background

Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom.

### Indication

For the Short-term treatment of intractable insomnia for patients habituated to barbiturates

### Pharmacodynamics

Secobarbital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.

### Mechanism of Action

Gamma-aminobutyric acid receptor subunit alpha-2
Potentiator
Gamma-aminobutyric acid receptor subunit alpha-3
Potentiator
Gamma-aminobutyric acid receptor subunit alpha-4
Potentiator
+ 3 more targets

### Toxicity

Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Secobarbital is combined with 1,2-Benzodiazepine.
Abacavir
Secobarbital may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abaloparatide
Secobarbital may increase the hypotensive activities of Abaloparatide.
Abemaciclib
The metabolism of Abemaciclib can be increased when combined with Secobarbital.
Acalabrutinib
The metabolism of Acalabrutinib can be increased when combined with Secobarbital.

### Food Interactions

Avoid alcohol. Taking with alcohol may cause additive CNS depression.
Take on an empty stomach. This may increase the rate of absorption.

## Chemical Information

**DrugBank ID:** DB00418

**Synonyms:** (±)-secobarbital
5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-allyl-5-(1-methylbutyl)barbituric acid
5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Quinalbarbitone
Secobarbital
Secobarbitalum
Secobarbitone

**Chemical Formula:** C
12
H
18
N
2
O
3

**SMILES:** CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O

**Weight:** Average: 238.2829
Monoisotopic: 238.131742452

**IUPAC Name:** 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

1

### Phase 0

0

### Phase 1

0

### Phase 2

0

### Phase 3

0

### Phase 4

0

### Therapeutic Categories

Barbiturates

### Summary

Secobarbital
is a barbiturate used for the short-term treatment of insomnia.

### Brand Names

Seconal Sodium

### Generic Name

Secobarbital

### DrugBank Accession Number

DB00418

### Groups

Approved, Vet approved

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Secobarbital (DB00418)
×
Close

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Treatment of
Insomnia
••••••••••••
Create Account
Create Account

### Associated Therapies

Anesthetic premedication therapy

### Mechanism of action

Secobarbital binds at a distinct binding site associated with a Cl
-
ionopore at the GABA
A
receptor, increasing the duration of time for which the Cl
-
ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Target
Actions
Organism
A
Gamma-aminobutyric acid receptor subunit alpha-2
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-3
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-4
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-5
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-6
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-1
potentiator
Humans
U
Neuronal acetylcholine receptor subunit alpha-4
antagonist
Humans
U
Neuronal acetylcholine receptor subunit alpha-7
antagonist
Humans
U
Glutamate receptor 2
antagonist
Humans
U
Glutamate receptor ionotropic, kainate 2
antagonist
Humans
U
NMDA receptor
antagonist
Humans

### Route of elimination

Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine and, less commonly, in the feces.

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Secobarbital sodium
XBP604F6UM
309-43-3
AXXJTNXVUHVOJW-UHFFFAOYSA-M

### International/Other Brands

Seconal
/
Tuinal

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Seconal Sodium
Capsule
100 mg/1
Oral
Ranbaxy Italia S.P.A.
2007-01-11
Not applicable
US

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Seconal Sodium
Capsule
100 mg/1
Oral
Bausch Health, Canada Inc.
1983-10-03
Not applicable
US
Seconal Sodium
Capsule
100 mg/1
Oral
Marathon Pharmaceuticals
1983-10-03
2016-01-14
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Tuinal Pulvule 303
Secobarbital sodium
(50 mg)
+
Amobarbital sodium
(50 mg)
Capsule
Oral
Pharmascience Inc
1945-12-31
2004-03-05
Canada
Tuinal Pulvule 304
Secobarbital sodium
(100 mg / cap)
+
Amobarbital sodium
(100 mg / cap)
Capsule
Oral
Pharmascience Inc
1945-12-31
2004-03-05
Canada

### ATC Codes

N05CB01 — Combinations of barbiturates
N05CB — Barbiturates, combinations
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM
N05CA06 — Secobarbital
N05CA — Barbiturates, plain
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Adjuvants
Adjuvants, Anesthesia
Anticholinergic Agents
Anticonvulsants
Barbiturates
Barbiturates, Plain
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP1A2 Inducers
Cytochrome P-450 CYP1A2 Inducers (strength unknown)
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C19 Inducers (strength unknown)
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C8 Inducers (strong)
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP2C9 Inducers (strength unknown)
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 CYP3A4 Inducers
Cytochrome P-450 CYP3A4 Inducers (strength unknown)
Cytochrome P-450 Enzyme Inducers
Drugs that are Mainly Renally Excreted
GABA Agents
GABA Modulators
Hypnotics and Sedatives
Nervous System
Neurotransmitter Agents
Nicotinic Antagonists
Psycholeptics
Pyrimidines
Pyrimidinones

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Barbituric acid derivatives
Alternative Parents
N-acyl ureas
/
Diazinanes
/
Dicarboximides
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organonitrogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
Substituents
1,3-diazinane
/
Aliphatic heteromonocyclic compound
/
Azacycle
/
Barbiturate
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxylic acid derivative
/
Dicarboximide
/
Hydrocarbon derivative
/
N-acyl urea
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
barbiturates (
CHEBI:9073
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Diazines

### Sub Class

Pyrimidines and pyrimidine derivatives

### Direct Parent

Barbituric acid derivatives

### Alternative Parents

N-acyl ureas
/
Diazinanes
/
Dicarboximides
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organonitrogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds

### Substituents

1,3-diazinane
/
Aliphatic heteromonocyclic compound
/
Azacycle
/
Barbiturate
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxylic acid derivative
/
Dicarboximide
/
Hydrocarbon derivative
/
N-acyl urea

### Molecular Framework

Aliphatic heteromonocyclic compounds

### External Descriptors

barbiturates (
CHEBI:9073
)

### Affected organisms

Humans and other mammals

### UNII

1P7H87IN75

### CAS number

76-73-3

### InChI Key

KQPKPCNLIDLUMF-UHFFFAOYSA-N

### InChI

InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)

### External Links

Human Metabolome Database
HMDB0014562
KEGG Drug
D00430
PubChem Compound
5193
PubChem Substance
46508708
ChemSpider
5005
RxNav
9624
ChEBI
9073
ChEMBL
CHEMBL447
Therapeutic Targets Database
DAP000674
PharmGKB
PA164784035
Drugs.com
Drugs.com Drug Page
Wikipedia
Secobarbital

### Human Metabolome Database

HMDB0014562

### KEGG Drug

D00430

### PubChem Compound

5193

### PubChem Substance

46508708

### ChemSpider

5005

### RxNav

9624

### ChEBI

9073

### ChEMBL

CHEMBL447

### Therapeutic Targets Database

DAP000674

### PharmGKB

PA164784035

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Secobarbital

### MSDS

Download
(48.6 KB)

### Manufacturers

Anabolic inc
Barr laboratories inc
Everylife
Halsey drug co inc
Ivax pharmaceuticals inc
Kv pharmaceutical co
Lannett co inc
Parke davis div warner lambert co
L perrigo co
Purepac pharmaceutical co
Valeant pharmaceuticals international
Vitarine pharmaceuticals inc
Watson laboratories inc
West ward pharmaceutical corp
Whiteworth towne paulsen inc
Wyeth ayerst laboratories
Ranbaxy pharmaceuticals inc
Elkins sinn div ah robins co inc
Eli lilly and co

### Packagers

Marathon Pharmaceuticals
Ohm Laboratories Inc.
Ranbaxy Laboratories

### Dosage Forms

Form
Route
Strength
Capsule
Oral
100 mg / cap
Capsule
Oral
100 mg/1
Capsule
Oral

### Prices

Unit description
Cost
Unit
Seconal 100 mg capsule
5.23USD
capsule
Seconal sodium 100 mg capsule
4.91USD
capsule
Seconal sodium 100 mg pulvul
0.93USD
each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
100 °C
PhysProp
water solubility
550 mg/L
Not Available
logP
1.97
HANSCH,C ET AL. (1995)
pKa
7.8
WOLLWEBER,H (1989)

### Predicted Properties

Property
Value
Source
Water Solubility
1.21 mg/mL
ALOGPS
logP
2.2
ALOGPS
logP
2.03
Chemaxon
logS
-2.3
ALOGPS
pKa (Strongest Acidic)
7.48
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
2
Chemaxon
Polar Surface Area
75.27 Å
2
Chemaxon
Rotatable Bond Count
5
Chemaxon
Refractivity
62.65 m
3
·mol
-1
Chemaxon
Polarizability
24.33 Å
3
Chemaxon
Number of Rings
1
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9331
Blood Brain Barrier
+
0.9762
Caco-2 permeable
-
0.5792
P-glycoprotein substrate
Substrate
0.6367
P-glycoprotein inhibitor I
Non-inhibitor
0.5256
P-glycoprotein inhibitor II
Non-inhibitor
0.9756
Renal organic cation transporter
Non-inhibitor
0.911
CYP450 2C9 substrate
Non-substrate
0.7863
CYP450 2D6 substrate
Non-substrate
0.9116
CYP450 3A4 substrate
Non-substrate
0.736
CYP450 1A2 substrate
Non-inhibitor
0.8707
CYP450 2C9 inhibitor
Non-inhibitor
0.7679
CYP450 2D6 inhibitor
Non-inhibitor
0.9276
CYP450 2C19 inhibitor
Non-inhibitor
0.7353
CYP450 3A4 inhibitor
Non-inhibitor
0.8902
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.9176
Ames test
Non AMES toxic
0.6131
Carcinogenicity
Non-carcinogens
0.8977
Biodegradation
Not ready biodegradable
0.9868
Rat acute toxicity
3.0894 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9603
hERG inhibition (predictor II)
Non-inhibitor
0.9471
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(9.04 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-00fv-9640000000-bd64b937d195fac13712
GC-MS Spectrum - EI-B
GC-MS
splash10-0006-9400000000-7060c19b726fabf79a65
GC-MS Spectrum - CI-B
GC-MS
splash10-000i-0090000000-cd7b7b08df2b25a36a42
Mass Spectrum (Electron Ionization)
MS
splash10-014i-6900000000-eb3ae85faebb012ef83b
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-000i-0190000000-db13804e78045568d611
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00ri-0590000000-c384be57f72d30b1df38
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-000i-1090000000-0e9ded2891f45c864e86
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9000000000-597397ec99a312feb491
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0ay4-2910000000-75606be9eabe8fd53d5e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-8900000000-8d8b9a5b9a2ca50f3657
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0ldj-2910000000-9f39dfaa8d3de2778dbf
1H NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
162.8150565
predicted
DarkChem Lite v0.1.0
[M-H]-
154.30089
predicted
DeepCCS 1.0 (2019)
[M+H]+
163.5643565
predicted
DarkChem Lite v0.1.0
[M+H]+
156.6589
predicted
DeepCCS 1.0 (2019)
[M+Na]+
163.1390565
predicted
DarkChem Lite v0.1.0
[M+Na]+
164.21568
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Inducer

### General Function

A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599, PubMed:7574697, PubMed:9435160, PubMed:9866708). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599, PubMed:7574697, PubMed:9435160, PubMed:9866708). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:15766564, PubMed:19965576, PubMed:7574697, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9435160, PubMed:9866708). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031)

### Specific Function

(R)-limonene 6-monooxygenase activity

### Gene Name

CYP2C9

### Uniprot ID

P11712

### Uniprot Name

Cytochrome P450 2C9

### Molecular Weight

55627.365 Da

### Curator comments

Secobarbital is a member of the barbiturate drug class, which are known to induce CYP2C9.

`,
  "isomerdesign": `# Secobarbital
*Source: https://isomerdesign.com/PiHKAL/explore.php?id=3992*

## Chemical Data

**IUPAC Name:** 5-(Pentan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione

**Molecular Formula:** C12H18N2O3

**Molecular Weight:** 238.283

**SMILES:** \`CCCC(C1(CC=C)C(=O)NC(=O)NC1=O)C\`

**InChI:** \`InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)\`

## External References

- [](https://en.wikipedia.org/wiki/Markush_structure)
- [5005](https://www.chemspider.com/Chemical-Structure.5005.html/)
- [5193](https://pubchem.ncbi.nlm.nih.gov/compound/5193)
- [Q414788](https://www.wikidata.org/wiki/Q414788)
- [Secobarbital](https://en.wikipedia.org/wiki/Secobarbital)
`,
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/Secobarbital",
  "experiencesUrl": "https://www.reddit.com/search/?q=Secobarbital",
  "name": "Secobarbital",
  "aliases": [
    "secobarbitone",
    "seconal"
  ],
  "aliasesStr": "secobarbitone,seconal",
  "summary": "A Barbiturate derivative that possesses all the classic effects of todays Benzodiazepines, and the old Barbiturates. It's used in the treatment of Epilepsy, short term treatment for insomnia, and a preoperative medication for anaesthesia and anxiolysis for short surgical/diagnostic/therapeutic procedures.",
  "reagents": null,
  "classes": {
    "chemical": [
      "Barbiturates"
    ],
    "psychoactive": [
      "Depressant"
    ]
  },
  "toxicity": [
    "moderate toxicity"
  ],
  "addictionPotential": "extremely physically and psychologically addictive",
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "20 mg"
        },
        {
          "name": "Light",
          "value": "25 - 50 mg"
        },
        {
          "name": "Common",
          "value": "50 - 150 mg"
        },
        {
          "name": "Strong",
          "value": "150 - 300 mg"
        },
        {
          "name": "Heavy",
          "value": "300 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.25 - 1.0 hours"
        },
        {
          "name": "Peak",
          "value": "4.0 - 8.0 hours"
        },
        {
          "name": "Offset",
          "value": "2.0 - 4.0 hours"
        },
        {
          "name": "Total",
          "value": "6.0 - 10.0 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 24.0 hours"
        }
      ]
    }
  ],
  "interactions": null,
  "effects": "Emotion suppression, Dizziness, Physical euphoria, Delusion, Cognitive euphoria, Thought deceleration, Disinhibition, Sedation, Motor control loss, Respiratory depression, Pain relief, Decreased blood pressure, Muscle relaxation, Anxiety suppression, Compulsive redosing, Amnesia, Visual acuity suppression, Decreased libido, Seizure suppression, Analysis depression, Language depression",
  "categorized_effects": {
    "Physical effects": [
      "Dizziness",
      "Physical euphoria",
      "Sedation",
      "Motor control loss",
      "Respiratory depression",
      "Pain relief",
      "Decreased blood pressure",
      "Muscle relaxation",
      "Seizure suppression"
    ],
    "Mental effects": [
      "Emotion suppression",
      "Delusion",
      "Cognitive euphoria",
      "Thought deceleration",
      "Disinhibition",
      "Anxiety suppression",
      "Amnesia",
      "Analysis depression",
      "Language depression"
    ],
    "Sensory effects": [
      "Visual acuity suppression",
      "Decreased libido"
    ],
    "Uncategorized effects": [
      "Compulsive redosing"
    ]
  }
}`,
  "psychonautwiki": `# Secobarbital
*Source: https://psychonautwiki.org/wiki/Secobarbital*

## Dosage & Duration

### Oral

**Dosage:**
- Threshold: 20 mg
- Light: 25 - 50 mg
- Common: 50 - 150 mg
- Strong: 150 - 300 mg
- Heavy: 300 mg +

**Duration:**
- Total: 6 - 10 hours
- Onset: 15 - 60 minutes
- Peak: 4 - 8 hours
- Offset: 2 - 4 hours
- After effects: 1 - 24 hours
**Fatal [overdose](https://psychonautwiki.org/wiki/Overdose) may occur when [barbiturates](https://psychonautwiki.org/wiki/Barbiturates) are combined with other [depressants](https://psychonautwiki.org/wiki/Depressants) such as [opiates](https://psychonautwiki.org/wiki/Opiates) , [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepines) , [gabapentinoids](https://psychonautwiki.org/wiki/Gabapentinoids) , [thienodiazepines](https://psychonautwiki.org/wiki/Thienodiazepines) , [alcohol](https://psychonautwiki.org/wiki/Alcohol) or other [GABAergic substances](https://psychonautwiki.org/wiki/GABA#GABA_receptors) .**
 
It is strongly discouraged to combine these substances, particularly in [common](https://psychonautwiki.org/wiki/Common) to [heavy](https://psychonautwiki.org/wiki/Heavy) doses.
**Secobarbital** , also known as **secobarbitone** in British English and by the brand name **Seconal** , is a short-acting psychoactive drug of the [barbiturate](https://psychonautwiki.org/wiki/Barbiturate) class which produces powerful anxiolytic, hypnotic, muscle relaxant and amnesic effects. The combination drug **Tuinal** has a combination of secobarbital and amobarbital. Secobarbital is used medically as a hypnotic for the short-term treatment of insomnia and as an [anticonvulsant](https://psychonautwiki.org/wiki/Seizure_suppression) in emergency situations, such as status epilepticus. Secobarbital works in a similar fashion to [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepine) , however, barbiturates bind to a different and distinct allosteric site on the GABA A receptor.

Compared to other barbiturates such as [phenobarbital](https://psychonautwiki.org/wiki/Phenobarbital) , secobarbital has a prompt onset of action, generally working within fifteen minutes of ingestion. Secobarbital's anxiolytic effects may last for up to 24 hours after the primary effects have worn off.

Secobarbital, like most short-acting barbiturates, is deemed to be extremely addictive. The abrupt discontinuation of secobarbital in dependent individuals may be life-threatening and lead to [seizures](https://psychonautwiki.org/wiki/Seizure) and even death . Secobarbital drastically enhances the effects of other [depressants](https://psychonautwiki.org/wiki/Depressant) such as [alcohol](https://psychonautwiki.org/wiki/Alcohol) , and concurrent use may lead to [respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression) and possibly death.

## Chemistry

Secobarbital is a drug of the [barbiturate](https://psychonautwiki.org/wiki/Barbiturate) class. Barbiturate drugs contain the backbone of barbituric acid. Secobarbital has a propenyl, and a methylpentane substitution on the 5-position of the barbituric acid backbone which gives it its unique pharmacological effects. The empirical formula of secobarbital is C 12 H 18 N 2 O 3 and has a molar mass of 238.283 grams per mole.

## Pharmacology

Barbiturates behave similarly to [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepine) . Secobarbital binds to an allosteric site on the GABA A receptor and potentiates the effects of the endogenous ligand, [gamma-aminobutyric acid](https://psychonautwiki.org/wiki/GABA) . When barbiturates bind to the GABA A receptor, it causes the ion pore to open for extended periods of time, causing an increase of intracellular chlorine ion concentrations. As this site is the most prolific inhibitory receptor set within the brain, its modulation results in the [sedating](https://psychonautwiki.org/wiki/Sedating) (or [calming effects](https://psychonautwiki.org/wiki/Anxiety_suppression) ) of barbiturates on the nervous system.

Around 45-60% of the secobarbital binds to membrane proteins. Secobarbital is metabolized in the liver and excreted by the kidneys. Its biological half-life is from 15 to 40 hours.

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Sedation](https://psychonautwiki.org/wiki/Sedation)** - In terms of energy level alterations, this drug has the potential to be extremely sedating and often results in an overwhelmingly lethargic state. At higher levels, this causes users to suddenly feel as if they are extremely sleep deprived and have not slept for days, forcing them to sit down and generally feel as if they are constantly on the verge of passing out instead of engaging in physical activities. This sense of sleep deprivation increases proportional to dosage and eventually becomes powerful enough to force a person into complete unconsciousness.
- **[Motor control loss](https://psychonautwiki.org/wiki/Motor_control_loss)**
- **[Muscle relaxation](https://psychonautwiki.org/wiki/Muscle_relaxation)**
- **[Dizziness](https://psychonautwiki.org/wiki/Dizziness)**
- **[Decreased blood pressure](https://psychonautwiki.org/wiki/Decreased_blood_pressure)** - Barbiturates may decrease blood pressure in some individuals and have occasionally been used to reduce intracranial pressure.
- **[Respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression)**
- **[Seizure suppression](https://psychonautwiki.org/wiki/Seizure_suppression)**
- **[Physical euphoria](https://psychonautwiki.org/wiki/Physical_euphoria)** - Compared to other GABAergic [depressants](https://psychonautwiki.org/wiki/Depressant) , this effect is particularly strong.
- **[Decreased libido](https://psychonautwiki.org/wiki/Decreased_libido)**
- **[Pain relief](https://psychonautwiki.org/wiki/Pain_relief)** - Compared to other agents such as [opioids](https://psychonautwiki.org/wiki/Opioid) , this effect is generally considered to be quite weak. ### Visual effects
 
- - **[Acuity suppression](https://psychonautwiki.org/wiki/Acuity_suppression)** - Like many [depressants](https://psychonautwiki.org/wiki/Depressant) , high doses of secobarbital may cause blurred vision. ### Cognitive effects
 
- - **[Anxiety suppression](https://psychonautwiki.org/wiki/Anxiety_suppression)**
- **[Cognitive euphoria](https://psychonautwiki.org/wiki/Cognitive_euphoria)** - Compared to other GABAergic [depressants](https://psychonautwiki.org/wiki/Depressant) , this effect is particularly strong. The feeling itself can be described as an extremely strong feeling of relaxed contentment.
- **[Thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration)**
- **[Analysis suppression](https://psychonautwiki.org/wiki/Analysis_suppression)**
- **[Disinhibition](https://psychonautwiki.org/wiki/Disinhibition)**
- **[Amnesia](https://psychonautwiki.org/wiki/Amnesia)**
- **[Slurred speech](https://psychonautwiki.org/wiki/Language_suppression)** - At higher doses, secobarbital is known to cause slurred speech.
- **[Compulsive redosing](https://psychonautwiki.org/wiki/Compulsive_redosing)**
- **[Emotion suppression](https://psychonautwiki.org/wiki/Emotion_suppression)** - Although this compound primarily suppresses anxiety, it also dulls other emotions in a manner which is distinct but less intensive than that of [antipsychotics](https://psychonautwiki.org/wiki/Antipsychotic) .
- **[Delusions of sobriety](https://psychonautwiki.org/wiki/Delusions)** - This is the false belief that one is perfectly sober despite obvious evidence to the contrary, such as severe cognitive impairment and an inability to fully communicate with others. It most commonly occurs at heavy dosages.
### Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) . Additional experience reports can be found here:

- [Erowid Experience Vaults: Secobarbital](https://www.erowid.org/experiences/subs/exp_Pharms_Secobarbital.shtml)

## Toxicity and harm potential

Secobarbital likely has moderate toxicity relative to dose. However, secobarbital is [[Toxicity::potentially [lethal](https://psychonautwiki.org/wiki/Respiratory_depression) when mixed with [depressants](https://psychonautwiki.org/wiki/Depressants) like [alcohol](https://psychonautwiki.org/wiki/Alcohol) or [opioids](https://psychonautwiki.org/wiki/Opioids) . Secobarbital has a higher risk of death or serious adverse effects associated with concurrent [depressant](https://psychonautwiki.org/wiki/Depressant) use than other drugs such as benzodiazepines. There have been studies linking the use of barbiturates, particularly [phenobarbital](https://psychonautwiki.org/wiki/Phenobarbital) , with the development of cancer.

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this drug.

### Tolerance and addiction potential

Secobarbital is extremely physically and psychologically addictive. Barbiturate withdrawal is medically serious and can potentially cause a life-threatening withdrawal syndrome that can cause [seizures](https://psychonautwiki.org/wiki/Seizure) , [psychosis](https://psychonautwiki.org/wiki/Psychosis) , and death. Drugs that lower the seizure threshold, such as [tramadol](https://psychonautwiki.org/wiki/Tramadol) and [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) should be avoided during withdrawal. If an individual is addicted to a short-acting barbiturate such as secobarbital, switching to a longer acting drug such as [phenobarbital](https://psychonautwiki.org/wiki/Phenobarbital) may be of some benefit.

Tolerance will develop to the sedative-hypnotic effects of secobarbital after prolonged use. It is unknown exactly how long it takes for tolerance to reach baseline. Secobarbital presents cross-tolerance with all barbiturates, meaning that after its consumption, all barbiturates will have a reduced effect.

### Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be harmless in low doses of each but still increase the potential risk of death. [Independent research](https://www.google.com/) should always be done to ensure that a combination of two or more substances is safe before consumption.

- **[Depressants](https://psychonautwiki.org/wiki/Depressants)** ( *[1,4-Butanediol](https://psychonautwiki.org/wiki/1,4-Butanediol) , [2-methyl-2-butanol](https://psychonautwiki.org/wiki/2-methyl-2-butanol) , [alcohol](https://psychonautwiki.org/wiki/Alcohol) , [barbiturates](https://psychonautwiki.org/wiki/Barbiturates) , [GHB](https://psychonautwiki.org/wiki/GHB) / [GBL](https://psychonautwiki.org/wiki/GBL) , [methaqualone](https://psychonautwiki.org/wiki/Methaqualone) , [opioids](https://psychonautwiki.org/wiki/Opioids)* ) - This combination can result in dangerous or even fatal levels of [respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression) . These substances potentiate the [muscle relaxation](https://psychonautwiki.org/wiki/Muscle_relaxation) , [sedation](https://psychonautwiki.org/wiki/Sedation) and [amnesia](https://psychonautwiki.org/wiki/Amnesia) caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should try to fall asleep in the [recovery position](https://psychonautwiki.org/wiki/Recovery_position) or have a friend move them into it.Secobarbital is deemed to have an increased incidence of serious adverse effects when used concurrently with other depressants than other depressants.
- **[Dissociatives](https://psychonautwiki.org/wiki/Dissociatives)** - This combination can lead to an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [recovery position](https://psychonautwiki.org/wiki/Recovery_position) or have a friend move them into it.
- **[Stimulants](https://psychonautwiki.org/wiki/Stimulants)** - It is unsafe to combine barbiturates with [stimulants](https://psychonautwiki.org/wiki/Stimulant) due to the risk of excessive intoxication. Stimulants decrease the [sedative](https://psychonautwiki.org/wiki/Sedation) effect of barbiturates, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of barbiturates will be considerably increased, leading to intensified [disinhibition](https://psychonautwiki.org/wiki/Disinhibition) as well as other effects. If combined, one should strictly limit themselves to only dosing a certain amount of barbiturates per hour. This combination can also potentially result in severe dehydration if hydration is not monitored.

### Overdose

Barbiturate overdose may occur when a barbiturate is taken in extremely heavy quantities or concurrently with other depressants. This is particularly dangerous with other GABAergic depressants such as [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepine) and [alcohol](https://psychonautwiki.org/wiki/Alcohol) since they work in a similar fashion but bind to distinct allosteric sites on the GABA A receptor, thus their effects potentiate one another. Benzodiazepines increase the frequency in which the chlorine ion pore opens on the GABA A receptor while barbiturates increase the duration in which they are open, meaning when both are consumed, the ion pore will open more frequently and stay open longer . Barbiturate overdose is a medical emergency that may lead to a coma, permanent brain injury or death if not treated promptly and properly. Barbiturate overdose has an increased frequency of serious adverse effects when compared to other depressants.

Symptoms of a barbiturate overdose may include severe [thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration) , [slurred speech](https://psychonautwiki.org/wiki/Language_suppression) , [confusion](https://psychonautwiki.org/wiki/Confusion) , [delusions](https://psychonautwiki.org/wiki/Delusions) , [respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression) , coma or death.

## Legal status

Internationally, secobarbital is listed in Schedule II of the UN Convention on Psychotropic Substances.

- **Canada** : Secobarbital is a Schedule IV controlled substance.
- **Germany** : Secobarbital is controlled under Anlage III BtMG ( *Narcotics Act, Schedule III* ) It can only be prescribed on a narcotic prescription form.
- **Russia** : Secobarbital is a Schedule III controlled substance.
- **Switzerland** : Secobarbital is a controlled substance specifically named under Verzeichnis B. Medicinal use is permitted.
- **United Kingdom** : Secobarbitone is a Class B controlled substance.
- **United States** : Secobarbital is a Schedule II controlled substance.

## See also

- [Depressants](https://psychonautwiki.org/wiki/Depressant)
- [Barbiturates](https://psychonautwiki.org/wiki/Barbiturate) 
- [Phenobarbital](https://psychonautwiki.org/wiki/Phenobarbital)
- [Benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepine)
- [GABA](https://psychonautwiki.org/wiki/GABA)

## External links

- [Secobarbital (Wikipedia)](https://en.wikipedia.org/wiki/secobarbital)
- [Secobarbital (TiHKAL / Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=3992)
- [Secobarbital (DrugBank)](https://go.drugbank.com/drugs/DB00418)

## References
1. ↑ [Risks of Combining Depressants - TripSit](https://tripsit.me/combining-depressants/)
2. ↑ Sarrecchia, C., Sordillo, P., Conte, G., Rocchi, G. (December 1998). "[Barbiturate withdrawal syndrome: a case associated with the abuse of a headache medication]".*Annali Italiani Di Medicina Interna: Organo Ufficiale Della Societa Italiana Di Medicina Interna*.**13**(4): 237–239.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0393-9340](//www.worldcat.org/issn/0393-9340).
3. ↑ Roberts, I., Sydenham, E. (12 December 2012). Cochrane Injuries Group, ed.["Barbiturates for acute traumatic brain injury"](https://doi.wiley.com/10.1002/14651858.CD000033.pub2).*Cochrane Database of Systematic Reviews*.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/14651858.CD000033.pub2](//doi.org/10.1002%2F14651858.CD000033.pub2).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1465-1858](//www.worldcat.org/issn/1465-1858).
4. ↑ Nutt, D., King, L. A., Saulsbury, W., Blakemore, C. (24 March 2007).["Development of a rational scale to assess the harm of drugs of potential misuse"](https://www.sciencedirect.com/science/article/pii/S0140673607604644).*The Lancet*.**369**(9566): 1047–1053.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0140-6736(07)60464-4](//doi.org/10.1016%2FS0140-6736%2807%2960464-4).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0140-6736](//www.worldcat.org/issn/0140-6736).
5. ↑ Friedman, G. D., Habel, L. A. (1 June 1999).["Barbiturates and lung cancer: a re-evaluation"](https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/28.3.375).*International Journal of Epidemiology*.**28**(3): 375–379.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1093/ije/28.3.375](//doi.org/10.1093%2Fije%2F28.3.375).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0300-5771](//www.worldcat.org/issn/0300-5771).
6. ↑ Twyman, R. E., Rogers, C. J., Macdonald, R. L. (March 1989). "Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital".*Annals of Neurology*.**25**(3): 213–220.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/ana.410250302](//doi.org/10.1002%2Fana.410250302).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0364-5134](//www.worldcat.org/issn/0364-5134).
7. ↑ [Barbiturate intoxication and overdose: MedlinePlus Medical Encyclopedia](https://medlineplus.gov/ency/article/000951.htm)
8. ↑ UN Convention on Psychotropic Substances | [https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/1971_Schedules/Revision1_2015/ST_CND_1_ADD2_Rev1_e_V1600359.pdf](https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/1971_Schedules/Revision1_2015/ST_CND_1_ADD2_Rev1_e_V1600359.pdf)
9. ↑ Branch, L. S. (2022),[Consolidated federal laws of Canada, Controlled Drugs and Substances Act](https://laws-lois.justice.gc.ca/eng/acts/c-38.8/page-15.html)
10. ↑ ["Anlage III BtMG"](https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 26, 2019.
11. ↑ [Постановление Правительства РФ от 01.10.2012 N 1002 (ред. от 09.08.2019) “Об утверждении значительного, крупного и особо крупного размеров наркотических средств и психотропных веществ, а также значительного, крупного и особо крупного размеров для растений, содержащих наркотические средства или психотропные вещества, либо их частей, содержащих наркотические средства или психотропные вещества, для целей статей 228, 228.1, 229 и 229.1 Уголовного кодекса Российской Федерации” - КонсультантПлюс](https://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=331879&dst=15%2C-1&date=02.12.2019)
12. ↑ ["Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html)(in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
13. ↑ [Drugs penalties](https://www.gov.uk/penalties-drug-possession-dealing)
14. ↑ DEA Schedule II Drugs | [https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_12.htm](https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_12.htm)NewPP limit report Cached time: 20251218075809 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.04 seconds CPU time usage: 0.287 seconds Real time usage: 0.560 seconds Preprocessor visited node count: 1368/1000000 Post‐expand include size: 97130/2097152 bytes Template argument size: 11837/2097152 bytes Highest expansion depth: 12/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 18309/5000000 bytes Lua time usage: 0.200/7 seconds Lua virtual size: 7.54 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 448.662 1 -total 26.52% 118.988 5 Template:Citation 25.32% 113.595 5 Template:Cite_journal 15.86% 71.156 1 Template:Headerpanel 15.11% 67.792 1 Template:DepressantOD 14.76% 66.237 1 Template:SubstanceBox/Secobarbital 14.36% 64.430 1 Template:GenericPanel/warning 13.68% 61.388 1 Template:GenericPanel 13.67% 61.323 1 Template:SubstanceBox 6.64% 29.795 2 Template:Cite_web`,
  "tripsit-factsheets": `# Secobarbital
*Source: https://tripbot.tripsit.me/api/tripsit/getDrug/secobarbital*

## Classification
- **Categories:** depressant, habit-forming, barbiturate
- **Also known as:** seconal

## Dosage

### Oral
- **Common:** 50-150mg
- **Light:** 25-50mg
- **Strong:** 150-300mg

## Duration
- **Onset:** 15-30 minutes
- **Duration:** 6-10 hours
- **After Effects:** 1-24 hours
`,
  "wikipedia": `# Secobarbital
*Source: https://en.wikipedia.org/wiki/Secobarbital*

Secobarbital, sold under the brand name Seconal among others, is a short-acting barbiturate drug originally used for the treatment of insomnia. It was patented by Eli Lilly and Company in 1934 in the United States. It possesses anesthetic, anticonvulsant, anxiolytic, sedative, and hypnotic properties. In the United Kingdom, it was known as quinalbarbitone. Secobarbital is considered to be an obsolete sedative-hypnotic (sleeping pill) and has largely been replaced by the benzodiazepine family. It was widely abused, known on the street as "red devils" or "reds." Among barbiturates, secobarbital carries a particularly high risk of abuse and addiction, which is largely responsible for it falling out of use.

## Uses

### Medical

Secobarbital is used for managing symptoms of epilepsy and for short-term treatment of insomnia. It is also used as a preoperative medication to produce anesthesia and anxiolysis for short surgical, diagnostic, or therapeutic procedures which are minimally painful.

### Recreational and lethal use

Secobarbital was widely abused for recreational purposes in the 1960s, 1970s, and 1980s, and accidental overdose was associated with the drug. Lilly's Seconal came in a bright orange/red bullet-shaped capsule known as a Pulvule. Prescription use of secobarbital decreased beginning in the early 1980s, by which time benzodiazepines had become increasingly common. Secobarbital has acquired many nicknames, the most common being "reds," "red devils," or "red dillies" (because of the color of the capsules). Other common nicknames are "seccies," "Cardinals," "ruby slippers," and, according to the Wegman's School of Pharmacy curriculum, "red hearts". A less common nickname is "dolls"; this was partly responsible for the title of Jacqueline Susann's novel Valley of the Dolls, whose main characters use secobarbital and other such drugs.
Actresses Carole Landis, Judy Garland, Lupe Vélez, playwright Tennessee Williams, table tennis star Ruth Aarons and journalist Dorothy Kilgallen allegedly either died by suicide or of accidentally overdosing on secobarbital. Seconal was used to induce Fred Hampton into docility before he was then killed in his bed in the early hours of December 4, 1969.
In 1978, 1,000 pills of Seconal were recovered in Jonestown, along with substantial quantities of Valium, Thorazine, Talwin, Demerol, and other sedatives, hypnotics, and analgesics.

### Assisted dying

Human
Secobarbital is used in assisted dying, either euthanasia or palliative sedation.
In the Netherlands, individuals have two options for assisted dying: they can orally consume 100 mL of concentrated syrup containing either 15 grams of pentobarbital or 15 grams of secobarbital, or they can choose to have 2 grams of thiopental or 1 gram of propofol administered intravenously by a doctor, followed by a muscle relaxant. As of 2010, only 15% of those who died by physician-assisted suicide opted for orally consuming the lethal drug(s), the rest choosing to have the drugs administered intravenously by a doctor instead.
In the United States, secobarbital and pentobarbital are the most common drugs prescribed under physician aid-in-dying laws in Oregon since 1998, Washington since 2008, and Vermont since 2013.
In 2017, secobarbital was made available for physician-assisted suicide in Canada.
Animal
It is a component in the veterinary drug Somulose, used for euthanasia of horses and cattle.
The LD50 of secobarbital has been reported to be between 125 mg/kg (rat, oral) and 267 mg/kg (mouse, oral).

## Adverse effects

Possible side effects of secobarbital include:

Somnolence
Dizziness
Impaired motor functions
Impaired coordination
Impaired balance
Anxiety
Confusion
Irritability
Headache
Increased appetite
Nausea
Vomiting
Nightmares
Increased sensitivity to pain
Allergic reactions
Difficulty breathing
Edema
Urticaria

### Withdrawal

Secobarbital may produce psychological addiction and produces physical dependence if used for an extended period of time. Withdrawal symptoms may occur if long-term use is abruptly ended and can include:

Anxiety
Insomnia
Decreased appetite
Seizures
Tremors
Possible death as a result of withdrawal

## Availability

Ranbaxy Pharmaceuticals, an India-based company now predominantly owned by the Japanese company Daiichi Sankyo, obtained the rights to market and to use the trade name Seconal from Eli Lilly in 1998 and did so until September 2008. The actual manufacturer of Seconal subsequent to the time Eli Lilly manufactured the drug was Ohm Pharmaceuticals, a wholly owned subsidiary of Ranbaxy. The rights to market Seconal were then sold to Marathon Pharmaceuticals, which became the marketer and trade-name holder. At the time Marathon Pharmaceuticals obtained ownership of the brand name, the retail price for one 100 mg capsule (depending upon prescription size and pharmacy) averaged about one U.S. dollar. During the time Marathon owned the brand name, the company greatly increased the price of the drug. By February 2015, when Marathon sold the rights to Valeant Pharmaceuticals, the average retail price per 100 mg capsule had risen to over thirty dollars. Since its acquisition of the trade name, Valeant Pharmaceuticals made little, if any, change to the pricing of Seconal. Despite the price increases implemented by Marathon Pharmaceuticals, Seconal was still manufactured by Ohm. In the United States, Seconal is available only in 100 mg capsules, as a sodium salt. The salt is a white hygroscopic powder that is soluble in water and ethanol.
While generic versions of the drug were in existence after Eli Lilly's patent on Seconal expired, currently there are no companies that manufacture the drug generically in the United States. Until 2020, Valeant was the sole marketer of Seconal in the United States. As of 2021, Valeant discontinued the product, and Bausch Health became the sole supplier of Seconal. Bausch Health stopped manufacturing the product in January 2022.

### Secobarbital sodium

The sodium salt of secobarbital is classified separately from the free acid, as follows:

CAS number: 309-43-3
Chemical formula: C12H18N2NaO3
Molecular weight: 260.265
`,
};
